- Lantern is <$150m market cap biotech focused on AI-driven drug-discovery and development.
- This has proven to be an unpopular sector of biotech across the past 12 months, with a lack of tangible progress causing share prices of most companies to fall.
- Lantern has 2 clinical opportunities in never-smokers with NSCLC and Prostate cancer, and significant funds with which to fund trials and potentially in-license more assets.
- The company hopes to create a powerful drug development platform in RADR, its data store, but realistically a decade's more data may be required to generate meaningful insight.
- Near-term price catalysts seem to lack real promise, but you can never rule out a sudden breakthrough. Lantern could also interest investors with a long-term time frame looking for drug development exposure.
For further details see:
Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer